Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with a short median survival despite multimodal therapy. offered rationale for analyzing combination therapy with FTY720 and milatuzumab an anti-CD74 mAb. Treatment of MCL cell lines and main tumor cells with FTY720 and milatuzumab resulted in statistically significant enhanced cell death which was synergistic in blastic… Continue reading Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with a